These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25529873)

  • 41. Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted Images After Gadobenate Dimeglumine Administration.
    Weberling LD; Kieslich PJ; Kickingereder P; Wick W; Bendszus M; Schlemmer HP; Radbruch A
    Invest Radiol; 2015 Nov; 50(11):743-8. PubMed ID: 26352749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Visualization of the biliary tract using gadobenate dimeglumine: preliminary findings.
    Ergen FB; Akata D; Sarikaya B; Kerimoglu U; Hayran M; Akhan O; Hussain HK
    J Comput Assist Tomogr; 2008; 32(1):54-60. PubMed ID: 18303288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU; Reiser MF; Huber AM
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT.
    Marin D; Di Martino M; Guerrisi A; De Filippis G; Rossi M; Ginanni Corradini S; Masciangelo R; Catalano C; Passariello R
    Radiology; 2009 Apr; 251(1):85-95. PubMed ID: 19332848
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Initial experience on utility of gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted MR cholangiography in diagnosis of acute cholecystitis.
    Akpinar E; Turkbey B; Karcaaltincaba M; Balli O; Akkapulu N; Balas S; Tirnaksiz B; Akata D; Akhan O
    J Magn Reson Imaging; 2009 Sep; 30(3):578-85. PubMed ID: 19711404
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Half-dose gadobenate dimeglumine versus standard-dose gadodiamide in dynamic magnetic resonance imaging of non-cirrhotic livers: a retrospective intra-individual crossover comparison.
    Homayoon B; Diwakar H; Strovski E; Bakshi D; Harris AC; Thoeni RF; Chang SD
    Abdom Imaging; 2014 Oct; 39(5):955-62. PubMed ID: 24676875
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma.
    Cereser L; Furlan A; Bagatto D; Girometti R; Como G; Avellini C; Orsaria M; Zuiani C; Bazzocchi M
    J Comput Assist Tomogr; 2010; 34(5):706-11. PubMed ID: 20861773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Low-Dose Higher-Relaxivity and Standard-Dose Lower-Relaxivity Contrast Media for Delayed-Enhancement MRI: A Blinded Randomized Crossover Study.
    Cheong BY; Duran C; Preventza OA; Muthupillai R
    AJR Am J Roentgenol; 2015 Sep; 205(3):533-9. PubMed ID: 26295638
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Less is better? Intraindividual and interindividual comparison between 0.075 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadoterate meglumine for cranial MRI.
    Khouri Chalouhi K; Papini GDE; Bandirali M; Sconfienza LM; Di Leo G; Sardanelli F
    Eur J Radiol; 2014 Jul; 83(7):1245-1249. PubMed ID: 24816087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Contrast-enhanced sonography with SonoVue: enhancement patterns of benign focal liver lesions and correlation with dynamic gadobenate dimeglumine-enhanced MRI.
    Ricci P; Laghi A; Cantisani V; Paolantonio P; Pacella S; Pagliara E; Arduini F; Pasqualini V; Trippa F; Filpo M; Passariello R
    AJR Am J Roentgenol; 2005 Mar; 184(3):821-7. PubMed ID: 15728603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
    Thomeer MG; Willemssen FE; Biermann KK; El Addouli H; de Man RA; Ijzermans JN; Dwarkasing RS
    J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging.
    Rudolph A; von Knobelsdorff-Brenkenhoff F; Wassmuth R; Prothmann M; Utz W; Schulz-Menger J
    J Magn Reson Imaging; 2014 May; 39(5):1153-60. PubMed ID: 24151119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Efficacy of gadobenate dimeglumine vs gadopentetate dimeglumine in contrast- enhanced magnetic resonance imaging for diagnosis of solitary brain metastases].
    Wang QJ; Wang Y; Xu X; Xiao H; Ma L
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):1968-73. PubMed ID: 22200693
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.
    Peña CS; Saini S; Baron RL; Hamm BA; Morana G; Caudana R; Giovagnoni A; Villa A; Carriero A; Mathieu D; Bourne MW; Kirchin MA; Pirovano G; Spinazzi A
    Korean J Radiol; 2001; 2(4):210-5. PubMed ID: 11754328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
    Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
    AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A case of gadobenate dimeglumine-induced anaphylactic shock: a case report.
    Huang J; Liu Z; Jiang C; Xu L; Zheng W
    Ann Palliat Med; 2021 Jun; 10(6):7126-7131. PubMed ID: 34154335
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Time-delayed contrast-enhanced MRI improves detection of brain metastases and apparent treatment volumes.
    Kushnirsky M; Nguyen V; Katz JS; Steinklein J; Rosen L; Warshall C; Schulder M; Knisely JP
    J Neurosurg; 2016 Feb; 124(2):489-95. PubMed ID: 26361281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging.
    Kim H; Kim MJ; Park MS; Cha SW; Lim JS; Yoo HS; Kim KW
    J Comput Assist Tomogr; 2010 Jan; 34(1):113-20. PubMed ID: 20118733
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Investigation of the longitudinal relaxation rate of blood after gadobenate dimeglumine administration: sequence optimization, dynamic acquisition, and clinical impact for contrast-enhanced MR angiography of the carotid arteries.
    Neira C; Anzidei M; Napoli A; Kirchin MA; Cavallo Marincola B; Zaccagna F; Catalano C; Passariello R; Tedoldi F
    Invest Radiol; 2011 Dec; 46(12):774-82. PubMed ID: 21730871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gadobenate dimeglumine-enhanced liver MR imaging in cirrhotic patients: quantitative and qualitative comparison of 1-hour and 3-hour delayed images.
    Jeong WK; Byun JH; Lee SS; Won HJ; Kim KW; Shin YM; Kim PN; Lee MG
    J Magn Reson Imaging; 2011 Apr; 33(4):889-97. PubMed ID: 21448954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.